Pharma Mar (PHM) Hisse Özeti
Bir biyofarmasötik şirketi olan Pharma Mar, S.A., İspanya, İtalya, Almanya, İrlanda, Fransa, Avrupa Birliği'nin geri kalanı, Amerika Birleşik Devletleri ve uluslararası alanda onkolojide kullanılmak üzere biyo-aktif ilkelerin araştırılması, geliştirilmesi, üretimi ve ticarileştirilmesi ile uğraşmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 5/6 |
| Geçmiş Performans | 5/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 2/6 |
Ödüller
Risk Analizi
PHM Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharma Mar, S.A. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | €78.40 |
| 52 Haftanın En Yüksek Seviyesi | €105.20 |
| 52 Haftanın En Düşük Seviyesi | €64.00 |
| Beta | 0.43 |
| 1 Aylık Değişim | -0.51% |
| 3 Aylık Değişim | -21.83% |
| 1 Yıllık Değişim | -0.89% |
| 3 Yıllık Değişim | 131.68% |
| 5 Yıllık Değişim | 11.84% |
| Halka arzdan bu yana değişim | 65.40% |
Son Haberler & Güncellemeler
Analyst Estimates: Here's What Brokers Think Of Pharma Mar, S.A. (BME:PHM) After Its Half-Yearly Report
Last week saw the newest half-yearly earnings release from Pharma Mar, S.A. ( BME:PHM ), an important milestone in the...
PHM: Future Cancer Trial Progress And New Lung Cancer Approvals Will Matter
Analysts have raised their 12-month price target for Pharma Mar from €75 to €90, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and expected future P/E following new Street research coverage. What’s in the News for Pharma Mar Pharma Mar started a Phase 1/2 clinical trial of PM54 in combination with pembrolizumab for previously treated patients with advanced solid tumors, following US FDA IND approval in December 2025.
PHM: First Line Lung Cancer Maintenance Approvals Will Support Medium Term Upside
Analysts have reset their 12 month price target for Pharma Mar to €125, reflecting updated assumptions around a slightly higher discount rate, modestly stronger projected revenue growth and profit margins, and a marginally lower future P/E, while citing supportive recent Street research coverage. What’s in the News for Pharma Mar Zepzelca (lurbinectedin) did not meet the primary overall survival endpoint in the Phase III LAGOON confirmatory trial for relapsed metastatic small cell lung cancer, according to Jazz Pharmaceuticals and Pharma Mar.Recent updates
Analyst Estimates: Here's What Brokers Think Of Pharma Mar, S.A. (BME:PHM) After Its Half-Yearly Report
Last week saw the newest half-yearly earnings release from Pharma Mar, S.A. ( BME:PHM ), an important milestone in the...PHM: Future Cancer Trial Progress And New Lung Cancer Approvals Will Matter
Analysts have raised their 12-month price target for Pharma Mar from €75 to €90, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and expected future P/E following new Street research coverage. What’s in the News for Pharma Mar Pharma Mar started a Phase 1/2 clinical trial of PM54 in combination with pembrolizumab for previously treated patients with advanced solid tumors, following US FDA IND approval in December 2025.PHM: First Line Lung Cancer Maintenance Approvals Will Support Medium Term Upside
Analysts have reset their 12 month price target for Pharma Mar to €125, reflecting updated assumptions around a slightly higher discount rate, modestly stronger projected revenue growth and profit margins, and a marginally lower future P/E, while citing supportive recent Street research coverage. What’s in the News for Pharma Mar Zepzelca (lurbinectedin) did not meet the primary overall survival endpoint in the Phase III LAGOON confirmatory trial for relapsed metastatic small cell lung cancer, according to Jazz Pharmaceuticals and Pharma Mar.PHM: Asia Pacific Lung Cancer Approvals Will Drive Medium Term Upside Potential
Analysts have maintained their €125 price target on Pharma Mar, citing BTIG's recent bullish initiation and updated assumptions for slightly higher revenue, profit margins, and a modestly lower discount rate and P/E multiple. What's in the News European Commission approves Zepzelca (lurbinectedin) with atezolizumab (Tecentriq) as first-line maintenance therapy for adult patients with extensive-stage small cell lung cancer whose disease has not progressed after standard induction therapy, following a positive opinion from the EMA, based on the phase 3 IMforte trial (source: company announcement).PHM: Asia Pacific Lung Cancer Expansion Will Support Medium Term Upside Potential
Analysts have raised their price target on Pharma Mar from €118 to €125, citing new research that reflects updated assumptions on growth, profitability and future P/E expectations following fresh coverage with a bullish stance. Analyst Commentary Recent Street research coverage reflects a confident tone around Pharma Mar, with bullish analysts pointing to updated assumptions on growth, profitability and future P/E expectations as key supports for higher valuation ranges.Pharma Mar's (BME:PHM) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Pharma Mar, S.A.'s ( BME:PHM ) stock hasn't moved much. We did...There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Pharma Mar, S.A.'s ( BME:PHM ) robust earnings report didn't manage to move the market for its stock. We did some...Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Pharma Mar, S.A. ( BME:PHM ) last week reported its latest third-quarter results, which makes it a good time for...Is Pharma Mar (BME:PHM) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)
It's not a stretch to say that Pharma Mar, S.A.'s ( BME:PHM ) price-to-sales (or "P/S") ratio of 7.4x right now seems...Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.80 on 27th...Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
Pharma Mar, S.A. ( BME:PHM ) will increase its dividend from last year's comparable payment on the 27th of June to...
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit
The latest earnings release from Pharma Mar, S.A. ( BME:PHM ) disappointed investors. Our analysis found several...There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump
The Pharma Mar, S.A. ( BME:PHM ) share price has done very well over the last month, posting an excellent gain of 27...Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 55% gain in the last month alone. The...Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 27% gain in the last month alone...Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.65 on 14th...Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
Pharma Mar, S.A. ( BME:PHM ) shareholders would be excited to see that the share price has had a great month, posting a...Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Last week, you might have seen that Pharma Mar, S.A. ( BME:PHM ) released its annual result to the market. The early...Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pharma Mar fair value estimate is €52.37 Pharma Mar is...We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Pharma Mar, S.A.'s ( BME:PHM ) lackluster earnings announcement last week disappointed investors. We think that they...Hissedar Getirileri
| PHM | ES Biotechs | ES Pazar | |
|---|---|---|---|
| 7D | -0.8% | 2.1% | 1.7% |
| 1Y | -0.9% | 23.3% | 32.3% |
Getiri vs. Endüstri: PHM geçen yıl % 23.3 oranında getiri sağlayan Spanish Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: PHM geçen yıl % 32.3 oranında getiri sağlayan Spanish Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| PHM volatility | |
|---|---|
| PHM Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in ES Market | 6.5% |
| 10% least volatile stocks in ES Market | 0.6% |
İstikrarlı Hisse Senedi Fiyatı: PHM hisse senedi fiyatı, son 3 ayda Spanish piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: PHM 'nin haftalık oynaklığı ( 8% ) geçen yıl boyunca sabit kaldı, ancak hala Spanish hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1986 | 505 | Jose Fernandez Sousa-Faro | www.pharmamar.com |
Bir biyofarmasötik şirketi olan Pharma Mar, S.A., İspanya, İtalya, Almanya, İrlanda, Fransa, Avrupa Birliği'nin geri kalanı, Amerika Birleşik Devletleri ve uluslararası alanda onkolojide kullanılmak üzere biyo-aktif ilkelerin araştırılması, geliştirilmesi, üretimi ve ticarileştirilmesi ile uğraşmaktadır. Şirket, Onkoloji ve RNA İnterferans segmentleri aracılığıyla faaliyet göstermektedir. Yumuşak doku sarkomu ve yumurtalık kanseri tedavisi için Yondelis'i; R/R multipl miyelom tedavisi için Aplidin'i ve küçük hücreli akciğer kanseri hastalarını tedavi etmek için Zepzelca'yı geliştirmekte ve ticarileştirmektedir.
Pharma Mar, S.A. Temel Bilgiler Özeti
| PHM temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | €1.36b |
| Kazançlar(TTM) | €56.13m |
| Gelir(TTM) | €218.64m |
PHM aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| PHM gelir tablosu (TTM) | |
|---|---|
| Gelir | €218.64m |
| Gelir Maliyeti | €14.47m |
| Brüt Kâr | €204.17m |
| Diğer Giderler | €148.05m |
| Kazançlar | €56.13m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 3.24 |
| Brüt Marj | 93.38% |
| Net Kâr Marjı | 25.67% |
| Borç/Özkaynak Oranı | 17.2% |
PHM uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/09 00:42 |
| Gün Sonu Hisse Fiyatı | 2026/08/07 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Pharma Mar, S.A. 12 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Kambiz Yazdi | BTIG |